Press Releases
Relmada Therapeutics Announces Settlement of Legal Action with Laidlaw & Company
Relmada Announces FDA Fast Track Designation for d-Methadone for Adjunctive Treatment of Major Depressive Disorder
Relmada Therapeutics to Participate in the 2nd Annual Disruptive Growth & Healthcare Conference
Relmada Therapeutics to Participate in BIO CEO and Investor Conference
Relmada Announces FDA Acceptance of IND and Authorization to Commence Phase 2a Clinical Trial for d-Methadone
Relmada Therapeutics to Provide an Update on the Development Plan for LevoCap ER
Relmada Therapeutics to Present at Biotech Showcase 2017
Relmada Therapeutics to Present at LD Micro "Main Event" Investor Conference
Relmada Therapeutics to Present at the Sidoti & Company Fall 2016 Emerging Growth Convention
Relmada Therapeutics Announces Issuance of Key U.S. Patent Covering d-Methadone, an NMDA Receptor Antagonist, for the Treatment of Depression and Other Psychiatric Symptoms
